한국어
Quantus

Capricor Therapeutics

CAPR · Nasdaq
$9.40+1.29%
2026-09-04 close

Capricor Therapeutics last closed at $9.40 (+1.29%) on 2026-09-04. Listed on Nasdaq; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
277 picks
Next-day win rate
44.2%
Avg next-day
-0.28%
vs market
-0.51%p

Every new-high-plus-volume pick we actually published (US market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

C
Overall: 건강관리 585/745 · top 79%
Factor composite · relative position in sector

PER — · PBR 2.95 — own-history percentile 65/100 · 75/100

Open self-history band
PER65/100
PBR75/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 6.08
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
6.08
Beneish M-Score
-2.41

No statistical flag

Sloan accrual
-0.28%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

매출 하락 → 마진 압박 → 현금 악화

Critical

매출이 -11.5% 감소하며 영업이익률이 -95.6%에서 -191.1%로 하락했다. 영업현금흐름도 동반 감소하여 수익-현금 순환이 약화되고 있다.

Evidence

매출 YoY -11.5% (2023→2024)영업이익률 -95.6%→-191.1%영업CF -26→-40

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

5/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score5/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -180%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (-95.6% → -191.1%, -95.5%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

USAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 386 of 543, share 0%.

386 / 5430%revenue share

Who dominates this industry?

  1. 1CVS Health14.1%
  2. 2McKesson13.6%
  3. 3Cigna9.4%
  4. 4Cardinal Health8.4%
  5. 5Centene6.2%
  6. 6Capricor Therapeutics0%

Concentration

DistributedCR3 37.1%
HHI 642543 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
159.97
Direction
축소
Level
넓음
Years
21

Value lens

P90/P10
24.4
Median P/B
3.02
Level
넓음
n
463

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-191.1%
Interest coverage
-20.3x
Return on equity (ROE)
-27.8%

Operating margin −5pp

Operating loss
Interest coverageBase -20.3x adverse case -20.8x
Return on equity (ROE)Base -27.8% adverse case -31.5%

Revenue −15%

Interest coverage risk
Interest coverageBase -20.3x adverse case -17.2x
Return on equity (ROE)Base -27.8% adverse case -26.3%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -20.3x adverse case -16.4x
Return on equity (ROE)Base -27.8% adverse case -31%

Interest coverage limit

Already below the limit by 200.5pp

Interest coverage limit at an operating margin of 9.4%

Interest expense coverage threshold

Connections

AI-extracted related companies · for reference

Customers
Duchenne muscular dystrophy
Same theme
Cell and gene therapyExosome therapeutics
🔗 See in the full market map →

Recent filings

Filings for overseas stocks are on the way. For now we cover Korean stocks only.

About Capricor Therapeutics
What technical signals does Capricor Therapeutics (CAPR) have?
Capricor Therapeutics current technical signals: no active technical signal.
Is Capricor Therapeutics a cup-and-handle pattern?
No. Capricor Therapeutics has no valid cup-and-handle signal right now.
What are Capricor Therapeutics's financials and valuation?
Capricor Therapeutics's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy